I had a symptom of colon cancer and family history, so I got a colonoscopy. It was expensive, and insurance was a nightmare, ...

Exact Sciences’ first quarter results were met with a positive market response, reflecting notable improvements in commercial ...

Let’s dig into the relative performance of Natera (NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season. Over the next few years, immuno-oncology companies, ...

The ruling ensures continued coverage, without patient cost-sharing, of services including BRCA testing and colorectal cancer screening, potentially impacting firms like Exact Sciences.

Of the 30 companies included in the list, 24 firms saw their stock prices rise, four saw their share prices decline, and two saw their stock prices remain flat.

Regular screening can bend the odds in your favor when it comes to four types of cancers. The science is less clear for the ...

The number of colorectal cancer cases in people under 50 is rising worldwide, especially in high-income countries. Possible ...

The recent surge in early-onset colorectal cancer, particularly in adults under 50, has sparked urgent concerns about the ...

A considerable proportion of bowel preparation claims for screening colonoscopy involve patient cost-sharing, according to a research letter published online June 20 in Gastroenterology.

As Men’s Health Awareness Month comes to a close, Torrington Community Hospital and family medicine physician Dr. Issifi ...

June is Men’s Health Month, an important annual campaign raising awareness about preventable health issues and encouraging ...

Topline data were announced from a trial evaluating zanzalintinib plus atezolizumab in adults with previously treated non-MSI-high mCRC.